Universal Ibogaine: Fighting Opioid Dependency with Plant-Based Medicine

- October 7th, 2021

Universal Ibogaine has launched its campaign on the Investing News Network.

Universal Ibogaine (TSXV:IBO) is developing an ibogaine based drug franchise to treat addiction and related mental health issues. These treatments will be administered within a global network of owned and franchised state-of-the-art holistic treatment clinics.

Universal Ibogaine also owns and operates a traditional addiction recovery center where it will develop a state-of-the-art holistic pretreatment, detox and aftercare programs into which the ibogaine treatment protocol will be inserted upon successful completion of the human proof of concept study.

Universal Ibogaine’s Company Highlights

  • The only pure-play public ibogaine company in the world
  • Focused on Ibogaine drug development plus state-of-the-art treatment clinics
  • Co-Founder Dr. Alberto Sola has administered over 3700 ibogaine treatments, more than any other doctor in the world.
  • CEO Dr. Rami Batal has a 25-year successful track record in developing experimental medicines.
  • De-Risked bio-tech drug development backed by real world treatment data set.
  • Treatments to occur in a safe clinical environment, through the development of gold-standard addiction treatment clinics
  • Arranging for clinical trials to medicalize ibogaine in Canada, including securing contract research organization (CROs), drug supply, and institutional partners
  • Acquired an active addiction treatment center in Canada to perfect the wrap around treatments and roll out ibogaine once approved in Canada.
  • Partnering with Canadian First Nations to investigate treatment possibilities on sovereign indigenous territories.
  • Acquired land in Belize with an eye toward co-development of an addiction aftercare treatment center.

Leave a Reply